

Polyglot Approved for SBIR Phase II Grant

Morrisville, NC – September 28, 2006 - Polyglot Systems, Inc., announced today that it has been awarded an SBIR Phase II Grant of \$750,000 through the National Center on Minority Health and Health Disparities of the National Institutes of Health to continue development of ProLingua RX. ProLingua RX is a tool that enables pharmacists to communicate medication instructions to foreign language speaking patients in their native language. During Phase I, the pharmacy concept was defined and a working prototype was developed with assistance from local pharmacists and pharmacy organizations. “Feedback on our Phase I work from thought leaders across the pharmacy industry has been very positive. We are excited to use the Phase II Grant to complete our ProLingua RX product so that we can reduce medication errors among limited English proficient patients due to miscommunication,” says Dr. Charles Lee, Polyglot’s President and Founder. The grant will be spent down over a two year period.

About Polyglot™

Founded in 2001 by a physician who saw the need for more accessible translation services in hospitals, Polyglot develops innovative technology solutions to help people overcome language barriers and communicate more effectively. Headquartered in Morrisville, NC, Polyglot is financed by private and institutional investors. Visit www.pgssi.com for more information.

Polyglot and ProLingua are trademarks in the United States of Polyglot Systems, Inc. Other marks belong to their respective owners.

Contact:

Stuart Schantz
Polyglot Systems, Inc.
cell: 919.291.0576
stuart@pgssi.com